213 related articles for article (PubMed ID: 19635614)
1. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
Archer DF; Lewis V; Carr BR; Olivier S; Pickar JH
Fertil Steril; 2009 Sep; 92(3):1039-1044. PubMed ID: 19635614
[TBL] [Abstract][Full Text] [Related]
2. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.
Pickar JH; Yeh IT; Bachmann G; Speroff L
Fertil Steril; 2009 Sep; 92(3):1018-1024. PubMed ID: 19635613
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615
[TBL] [Abstract][Full Text] [Related]
4. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
Kagan R; Abreu P; Andrews E
Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946
[TBL] [Abstract][Full Text] [Related]
5. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
Palacios S; Currie H; Mikkola TS; Dragon E
Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
[TBL] [Abstract][Full Text] [Related]
6. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
[TBL] [Abstract][Full Text] [Related]
8. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
Pickar JH; Mirkin S
Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
11. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
[TBL] [Abstract][Full Text] [Related]
12. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
13. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
14. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
15. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
Kagan R
J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
[TBL] [Abstract][Full Text] [Related]
16. Initial investigation into the optimal dose ratio of conjugated estrogens and bazedoxifene: a double-blind, randomized, placebo-controlled phase 2 dose-finding study.
Pickar JH; Lavenberg J; Pan K; Komm BS
Menopause; 2018 Mar; 25(3):273-285. PubMed ID: 29088019
[TBL] [Abstract][Full Text] [Related]
17. Tissue-selective estrogen complexes for postmenopausal women.
Mirkin S; Komm BS
Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
[TBL] [Abstract][Full Text] [Related]
18. Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
Mirkin S; Komm B; Pickar JH
Womens Health (Lond); 2014 Mar; 10(2):135-46. PubMed ID: 24601804
[TBL] [Abstract][Full Text] [Related]
19. The effect of conjugated estrogens/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials.
Black D; Messig M; Yu CR; Assaf AR; Komm BS; Mirkin S; Boucher M
Menopause; 2016 Apr; 23(4):376-82. PubMed ID: 26694733
[TBL] [Abstract][Full Text] [Related]
20. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
Komm BS; Mirkin S; Jenkins SN
Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
